Two Decades of Endocrine Silence: Severe Hyponatremia Presenting as Late-Onset Sheehan Syndrome

Alberto Jose Sanjuanelo Fontalvo1, Said Marien Clarete de la Rosa2, Jorge Fernando Quintero Arrieta3

  • 1Internal Medicine, University of Cartagena, Cartagena, COL.

Cureus
|August 26, 2026
PubMed

Sheehan syndrome is a rare but potentially fatal complication of postpartum hemorrhage caused by ischemic necrosis of the anterior pituitary gland. Although its incidence has decreased in countries with comprehensive obstetric care systems, it remains a significant cause of panhypopituitarism in regions lacking timely and adequate access to perinatal care. The clinical challenge lies in its insidious presentation: symptoms develop slowly and gradually, and the diagnosis may remain unrecognized for decades. We report the case of a 52-year-old woman who presented with a one-year history of progressive decline in general health, characterized by debilitating asthenia, somnolence, decreased appetite, and an unintentional 13-kg weight loss. Her obstetric history provided the crucial diagnostic clue: 21 years prior, her last delivery - an initially unattended home birth - was complicated by a retained placenta and severe hemorrhage, followed by total agalactia and permanent secondary amenorrhea. Initial laboratory evaluation revealed severe hyponatremia (119 mmol/L), normocytic anemia, and biochemical evidence of central hypothyroidism and adrenal insufficiency. Magnetic resonance imaging (MRI) confirmed an empty sella turcica. Sequential hormone replacement therapy was initiated - administering glucocorticoids before levothyroxine - resulting in the normalization of serum sodium levels and significant clinical improvement. The clinical triad of postpartum hemorrhage, agalactia, and secondary amenorrhea constitutes a critical diagnostic red flag. Timely recognition of Sheehan syndrome is essential not only for resolving acute complications such as hyponatremia, driven by secondary hypothyroidism and hypocortisolism, but also for preventing cardiometabolic complications and severe osteoporosis with a high fracture risk associated with untreated chronic hypopituitarism.

Related Concept Videos

Hyperosmolar Hyperglycemic State01:21

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...
Diabetes Insipidus II: Pathophysiology01:22

Diabetes Insipidus II: Pathophysiology

Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...
Diabetes Insipidus I: Introduction01:29

Diabetes Insipidus I: Introduction

Definition Diabetes insipidus is a disorder marked by the production of large amounts of dilute urine because of impaired vasopressin production, release, or kidney response. The lack of effective vasopressin action limits water reabsorption in the renal collecting ducts, which leads to excessive urinary water loss and intense thirst.Clinical PresentationIndividuals with diabetes insipidus report persistent thirst and very high urine output. In severe cases, fluid intake can reach up to 20...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...